The leukocytosis market size has grown strongly in recent years. It will grow from $5.13 billion in 2025 to $5.41 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to high prevalence of infectious diseases, increasing incidence of inflammatory disorders, growing cases of leukemia, reliance on conventional blood tests, expansion of hospital-based diagnostic services.
The leukocytosis market size is expected to see strong growth in the next few years. It will grow to $6.63 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to advancements in hematology diagnostics, rising adoption of personalized treatment approaches, growing awareness of early disease detection, increasing healthcare expenditure, expansion of laboratory automation. Major trends in the forecast period include increasing adoption of advanced blood diagnostics, growing focus on underlying disease-specific treatment, rising use of precision medicine in hematology, expansion of automated and high-throughput testing, increasing integration of clinical decision support systems.
The increasing prevalence of blood-related diseases is expected to drive the growth of the leukocytosis market in the coming years. Blood-related diseases are medical conditions that impact blood components, including red blood cells, white blood cells, platelets, or plasma. The occurrence of blood-related diseases is rising due to aging populations, as older adults are more prone to conditions such as anemia, leukemia, and clotting disorders because of declining immune function and cumulative health issues. These diseases often lead to elevated white blood cell counts, a key indicator of leukocytosis, emphasizing the need for improved early diagnosis, better monitoring tools, and more effective treatment options. For example, in 2024, the American Cancer Society, a US-based cancer organization, reported 62,770 new cases of leukemia, up from 59,610 cases in 2023. Thus, the growing incidence of blood-related diseases is fueling the expansion of the leukocytosis market.
Major companies operating in the leukocytosis market are concentrating on incorporating artificial intelligence into diagnostic systems to improve early detection, diagnostic precision, and personalized treatment planning. Artificial intelligence in diagnostic systems involves the application of AI technologies such as machine learning, deep learning, and natural language processing to analyze medical data and assist or automate disease diagnosis. For example, in December 2024, Koninklijke Philips NV, a Netherlands-based healthcare company, introduced the CT 5300 system. It integrates proprietary AI technologies to optimize computed tomography (CT) imaging workflows. The system includes the computed tomography smart workflow, featuring AI-driven tools such as precise position, precise cardiac, and precise brain, which simplify scan preparation, enhance diagnostic accuracy, and minimize radiation exposure.
In February 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired ImmunoGen Inc. for an undisclosed amount. This acquisition allows AbbVie to strengthen its oncology portfolio by leveraging ImmunoGen's expertise in antibody-drug conjugates (ADCs), boosting its capacity to develop targeted therapies for blood-related cancers and conditions such as leukocytosis. ImmunoGen Inc. is a US-based biotechnology company specializing in ADCs for the treatment of blood-related cancers like leukemia, which often lead to leukocytosis.
Major companies operating in the leukocytosis market are Pfizer Inc., Johnson & Johnson, Siemens Healthineers AG, Roche Diagnostics AG, Bristol Myers Squibb, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis International AG, Danaher Corporation, Merck KGaA, Becton Dickinson and Company (BD), Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics, Agilent Technologies Inc., Grifols SA, Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Beckman Coulter Diagnostics Inc., Bio-Rad Laboratories, Bio-Techne Corporation, NeoGenomics Laboratories Inc., DiaSorin S.p.A.
North America was the largest region in the leukocytosis market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the leukocytosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leukocytosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have moderately impacted the leukocytosis market by increasing costs of imported diagnostic equipment, laboratory reagents, and advanced imaging systems. Diagnostic segments such as automated blood analyzers and bone marrow biopsy tools are most affected, particularly in north america and europe due to reliance on global medical device supply chains. Higher procurement costs may impact diagnostic laboratories and hospital budgets. However, tariffs have encouraged local manufacturing of diagnostic consumables, strengthened regional supply chains, and supported long-term self-sufficiency in hematology diagnostics.
The leukocytosis market research report is one of a series of new reports that provides leukocytosis market statistics, including leukocytosis industry global market size, regional shares, competitors with a leukocytosis market share, detailed leukocytosis market segments, market trends and opportunities, and any further data you may need to thrive in the leukocytosis industry. This leukocytosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Leukocytosis is a condition characterized by an elevated white blood cell (WBC) count in the bloodstream. It commonly signals an underlying infection, inflammation, or immune response. The main goal of treating this condition is to support the body's defense mechanisms by increasing WBC levels to combat infections or promote healing.
The primary disease types associated with leukocytosis include infection, inflammation, leukemia, and stress response. Infections trigger leukocytosis as the immune system responds to invading pathogens by producing more white blood cells, especially neutrophils, to counter bacterial threats. Diagnosis of leukocytosis is carried out through blood tests, bone marrow biopsies, and imaging techniques. Management and treatment of the condition are facilitated through various distribution channels, such as hospital pharmacies, online pharmacies, and retail pharmacies. Key end users of leukocytosis-related diagnostics and treatments include hospitals, diagnostic laboratories, and research institutions.
The leukocytosis market includes revenues earned by entities through complete blood count (CBC) testing, white blood cell differential analysis, monitoring and management of underlying conditions, development and administration of targeted therapeutics, and support for clinical research and drug trials focused on hematologic abnormalities. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The leukocytosis market size is expected to see strong growth in the next few years. It will grow to $6.63 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to advancements in hematology diagnostics, rising adoption of personalized treatment approaches, growing awareness of early disease detection, increasing healthcare expenditure, expansion of laboratory automation. Major trends in the forecast period include increasing adoption of advanced blood diagnostics, growing focus on underlying disease-specific treatment, rising use of precision medicine in hematology, expansion of automated and high-throughput testing, increasing integration of clinical decision support systems.
The increasing prevalence of blood-related diseases is expected to drive the growth of the leukocytosis market in the coming years. Blood-related diseases are medical conditions that impact blood components, including red blood cells, white blood cells, platelets, or plasma. The occurrence of blood-related diseases is rising due to aging populations, as older adults are more prone to conditions such as anemia, leukemia, and clotting disorders because of declining immune function and cumulative health issues. These diseases often lead to elevated white blood cell counts, a key indicator of leukocytosis, emphasizing the need for improved early diagnosis, better monitoring tools, and more effective treatment options. For example, in 2024, the American Cancer Society, a US-based cancer organization, reported 62,770 new cases of leukemia, up from 59,610 cases in 2023. Thus, the growing incidence of blood-related diseases is fueling the expansion of the leukocytosis market.
Major companies operating in the leukocytosis market are concentrating on incorporating artificial intelligence into diagnostic systems to improve early detection, diagnostic precision, and personalized treatment planning. Artificial intelligence in diagnostic systems involves the application of AI technologies such as machine learning, deep learning, and natural language processing to analyze medical data and assist or automate disease diagnosis. For example, in December 2024, Koninklijke Philips NV, a Netherlands-based healthcare company, introduced the CT 5300 system. It integrates proprietary AI technologies to optimize computed tomography (CT) imaging workflows. The system includes the computed tomography smart workflow, featuring AI-driven tools such as precise position, precise cardiac, and precise brain, which simplify scan preparation, enhance diagnostic accuracy, and minimize radiation exposure.
In February 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired ImmunoGen Inc. for an undisclosed amount. This acquisition allows AbbVie to strengthen its oncology portfolio by leveraging ImmunoGen's expertise in antibody-drug conjugates (ADCs), boosting its capacity to develop targeted therapies for blood-related cancers and conditions such as leukocytosis. ImmunoGen Inc. is a US-based biotechnology company specializing in ADCs for the treatment of blood-related cancers like leukemia, which often lead to leukocytosis.
Major companies operating in the leukocytosis market are Pfizer Inc., Johnson & Johnson, Siemens Healthineers AG, Roche Diagnostics AG, Bristol Myers Squibb, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis International AG, Danaher Corporation, Merck KGaA, Becton Dickinson and Company (BD), Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics, Agilent Technologies Inc., Grifols SA, Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Beckman Coulter Diagnostics Inc., Bio-Rad Laboratories, Bio-Techne Corporation, NeoGenomics Laboratories Inc., DiaSorin S.p.A.
North America was the largest region in the leukocytosis market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the leukocytosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leukocytosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have moderately impacted the leukocytosis market by increasing costs of imported diagnostic equipment, laboratory reagents, and advanced imaging systems. Diagnostic segments such as automated blood analyzers and bone marrow biopsy tools are most affected, particularly in north america and europe due to reliance on global medical device supply chains. Higher procurement costs may impact diagnostic laboratories and hospital budgets. However, tariffs have encouraged local manufacturing of diagnostic consumables, strengthened regional supply chains, and supported long-term self-sufficiency in hematology diagnostics.
The leukocytosis market research report is one of a series of new reports that provides leukocytosis market statistics, including leukocytosis industry global market size, regional shares, competitors with a leukocytosis market share, detailed leukocytosis market segments, market trends and opportunities, and any further data you may need to thrive in the leukocytosis industry. This leukocytosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Leukocytosis is a condition characterized by an elevated white blood cell (WBC) count in the bloodstream. It commonly signals an underlying infection, inflammation, or immune response. The main goal of treating this condition is to support the body's defense mechanisms by increasing WBC levels to combat infections or promote healing.
The primary disease types associated with leukocytosis include infection, inflammation, leukemia, and stress response. Infections trigger leukocytosis as the immune system responds to invading pathogens by producing more white blood cells, especially neutrophils, to counter bacterial threats. Diagnosis of leukocytosis is carried out through blood tests, bone marrow biopsies, and imaging techniques. Management and treatment of the condition are facilitated through various distribution channels, such as hospital pharmacies, online pharmacies, and retail pharmacies. Key end users of leukocytosis-related diagnostics and treatments include hospitals, diagnostic laboratories, and research institutions.
The leukocytosis market includes revenues earned by entities through complete blood count (CBC) testing, white blood cell differential analysis, monitoring and management of underlying conditions, development and administration of targeted therapeutics, and support for clinical research and drug trials focused on hematologic abnormalities. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Leukocytosis Market Characteristics
3. Leukocytosis Market Supply Chain Analysis
4. Global Leukocytosis Market Trends and Strategies
5. Leukocytosis Market Analysis of End Use Industries
7. Global Leukocytosis Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Leukocytosis Total Addressable Market (TAM) Analysis for the Market
9. Leukocytosis Market Segmentation
10. Leukocytosis Market Regional and Country Analysis
11. Asia-Pacific Leukocytosis Market
12. China Leukocytosis Market
13. India Leukocytosis Market
14. Japan Leukocytosis Market
15. Australia Leukocytosis Market
16. Indonesia Leukocytosis Market
17. South Korea Leukocytosis Market
18. Taiwan Leukocytosis Market
19. South East Asia Leukocytosis Market
20. Western Europe Leukocytosis Market
21. UK Leukocytosis Market
22. Germany Leukocytosis Market
23. France Leukocytosis Market
24. Italy Leukocytosis Market
25. Spain Leukocytosis Market
26. Eastern Europe Leukocytosis Market
27. Russia Leukocytosis Market
28. North America Leukocytosis Market
29. USA Leukocytosis Market
30. Canada Leukocytosis Market
31. South America Leukocytosis Market
32. Brazil Leukocytosis Market
33. Middle East Leukocytosis Market
34. Africa Leukocytosis Market
36. Leukocytosis Market Competitive Landscape and Company Profiles
37. Leukocytosis Market Other Major and Innovative Companies
40. Leukocytosis Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Leukocytosis Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses leukocytosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for leukocytosis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The leukocytosis market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Disease Type: Infection; Leukemia2) By Diagnosis Type: Blood Tests; Bone Marrow Biopsy
3) By End User: Hospitals; Diagnostic Laboratories
Subsegments:
1) By Infection: Bacterial Infections; Viral Infections; Parasitic Infections; Fungal Infections2) By Leukemia: Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Acute Lymphoblastic Leukemia (ALL) with Hyperleukocytosis
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Siemens Healthineers AG; Roche Diagnostics AG; Bristol Myers Squibb; Thermo Fisher Scientific Inc.; Abbott Laboratories; Novartis International AG; Danaher Corporation; Merck KGaA; Becton Dickinson and Company (BD); Laboratory Corporation of America Holdings (LabCorp); Quest Diagnostics; Agilent Technologies Inc.; Grifols SA; Hologic Inc.; Illumina Inc.; PerkinElmer Inc.; Sysmex Corporation; Beckman Coulter Diagnostics Inc.; Bio-Rad Laboratories; Bio-Techne Corporation; NeoGenomics Laboratories Inc.; DiaSorin S.p.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Leukocytosis market report include:- Pfizer Inc.
- Johnson & Johnson
- Siemens Healthineers AG
- Roche Diagnostics AG
- Bristol Myers Squibb
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Novartis International AG
- Danaher Corporation
- Merck KGaA
- Becton Dickinson and Company (BD)
- Laboratory Corporation of America Holdings (LabCorp)
- Quest Diagnostics
- Agilent Technologies Inc.
- Grifols SA
- Hologic Inc.
- Illumina Inc.
- PerkinElmer Inc.
- Sysmex Corporation
- Beckman Coulter Diagnostics Inc.
- Bio-Rad Laboratories
- Bio-Techne Corporation
- NeoGenomics Laboratories Inc.
- DiaSorin S.p.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.41 Billion |
| Forecasted Market Value ( USD | $ 6.63 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
